Liso-cell is one of the three drugs that comprises the $9/sh CVR for prior CELG shareholders (#msg-145844551); liso-cel has an FDA-approval of 12/31/20 (6 weeks after the PDUFA date) for the CVR to pay out, so there’s now only 6 weeks of slack in the liso-cel schedule. The CVR (BMY-RI) is currently trading for about $4, -9%.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”